Abstract Background A pediatric Phase I trial was performed to determine the maximum‐
tolerated dose, dose‐limiting toxicities (DLTs), and pharmacokinetics (PK) of vorinostat and …

One of the main characteristics of carcinogenesis relies on genetic alterations in DNA and
epigenetic changes in histone and non-histone proteins. At the chromatin level, gene …

A novel class of colchicine-SAHA hybrids were designed and synthesised based on the
synergistic antitumor effect of tubulin inhibitors and histone deacetylases (HDAC) inhibitors …

Using Entinostat as a lead compound, 2-aminobenzamide and hydroxamate derivatives
have been designed and synthesized. The entire target compounds were investigated for …

Histone deacetylase (HDAC) appears to play an important role in the pathogenesis of acute
promyelocytic leukaemia (APL) as it is recruited by both PML–RARα and PLZF/RARα in …

The discovery of new small molecules and their testing in rational combination poses an
ongoing problem for rare diseases, in particular, for pediatric cancers such as …

Histone deacetylases (HDACs) are an emerging class of novel anti-cancer drug targets.
Recently, studies in adult cancers and in neuroblastoma have shown that individual HDAC …

Approximately 15,000 new cases of pediatric cancer are diagnosed yearly in Europe, with 8–
10% corresponding to neuroblastoma, a rare disease with an incidence of 8–9 cases per …

The epigenome of cancer cells is determined by DNA methylation and an array of post-
translational modifications of the core histones. Epigenetic abnormalities are commonly …

Histone deacetylases (HDAC) and histone acetyltransferases exert opposing enzymatic
activities that modulate the degree of acetylation of histones and other intracellular …